Inspiremd Stock Price, News & Analysis

InspireMD (NSPR) has achieved CE Mark approval under European MDR for its CGuard Prime Embolic Prevention System, a carotid stent system designed to prevent strokes. The CGuard Prime, featuring proprietary MicroNet mesh technology, was developed based on user feedback to enhance deliverability and deployment. The system works by trapping debris against vessel walls and preventing plaque prolapse and embolization that can lead to strokes. CEO Marvin Slosman highlighted this approval as a significant milestone, enabling commercial launch across CE-marked markets. The company plans to launch the same platform in the United States later in 2025, pending FDA approval, which would allow for unified platform deployment across their markets.

InspireMD (NSPR) has appointed Michael Lawless as its new Chief Financial Officer, effective by June 30, 2025, succeeding Craig Shore who served in the role for nearly 15 years. Lawless brings extensive healthcare industry experience, having previously served as CFO of Lifeward and the Life Sciences unit of Brooks Automation. As part of his compensation package, Lawless will receive 465,000 shares of restricted stock and options to purchase 212,000 shares, vesting over three years. The appointment comes at a crucial time as InspireMD prepares for the U.S. market launch of its CGuard Prime carotid stent system, designed for treating carotid artery disease and preventing stroke.

InspireMD (NSPR) reported Q1 2025 financial results, showing a 1.2% revenue increase to $1.53 million from $1.51 million in Q1 2024. The company reported a net loss of $11.17 million ($0.22 per share), compared to $7.03 million ($0.21 per share) in Q1 2024. Operating expenses increased 52.5% to $11.75 million due to U.S. sales force expansion. Cash position stood at $26.09 million as of March 31, 2025. The company continues engagement with FDA for CGuard Prime carotid stent system approval, anticipated in Q3 2025, while advancing commercial infrastructure for U.S. launch. The CGUARDIANS II pivotal study for TCAR procedures continues enrollment.

InspireMD (Nasdaq: NSPR), the developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has announced its upcoming participation at the Bank of America 2025 Healthcare Conference.

The presentation is scheduled for Wednesday, May 14, 2025, at 1:15PM Eastern Time (10:15AM Pacific Time). Interested parties can access both the live audio webcast and a 90-day replay through the "News & Events" section on InspireMD's official website at inspiremd.com/en/events/.

InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its first quarter 2025 financial results release for May 9, 2025.

The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via telephone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's website webcast.

InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for 11 new non-executive employees. The grants, consisting of 299,398 shares of restricted stock, were approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The grants, dated April 1, 2025, were issued outside of InspireMD's 2021 Equity Compensation Plan and under the company's 2024 Inducement Plan. The restricted stock follows a three-year vesting schedule: one-third vests after the first year, with the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.

InspireMD (Nasdaq: NSPR), the developer of CGuard™ Prime carotid stent system for carotid artery disease treatment and stroke prevention, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The presentation is scheduled for Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. Investors and interested parties can access a live audio webcast of the presentation, with a replay available for 90 days through the company's website at inspiremd.com in the News & Events section.

InspireMD (NSPR) reported its Q4 and full-year 2024 financial results, highlighting record quarterly revenue of $1.95M and 3.5K units in served markets. The company achieved a 10.7% revenue increase in Q4 2024 compared to Q4 2023.

Key developments include the FDA engagement for CGuard Prime carotid stent system's PMA application, with anticipated approval in H1 2025. The company established its headquarters in Miami and initiated the CGUARDIANS II pivotal study for TCAR procedures.

Financial highlights: Full-year 2024 revenue increased 13% to $7.01M, though gross margin decreased to 21.5% from 29.1%. Q4 operating expenses rose 55.8% to $9.84M, primarily due to US personnel expansion and commercial preparation costs. The company ended 2024 with $34.64M in cash and marketable securities.

InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025.

The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via phone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's investor relations website.